Merck Stock Pullback but Outlook Remains Positive
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Stock Pullback: Merck (MRK) closed down 0.87% at $128.26 on Tuesday, breaking a six-session winning streak, despite a 13.62% gain during that period, outperforming the S&P 500's 0.80% decline.
- Key Drug Approval: On June 25, Merck's Keytruda in combination with Padcev was approved by the European Commission for first-line treatment of certain unresectable or metastatic urothelial carcinoma, leading to a nearly 4% stock increase that day and expanding its oncology franchise.
- Analyst Optimism: Seeking Alpha's ALLKA Research rated Merck a Buy, citing a strong oncology engine with continued momentum for Keytruda and a broad late-stage pipeline supporting long-term growth, while Gen Alpha viewed the recent stock weakness as a buying opportunity, suggesting concerns over Keytruda's patent cliff are priced in.
- Divergent Ratings: While most analysts maintain a Buy consensus on Merck, the Seeking Alpha Quant Rating system assigns a Hold rating, indicating mixed fundamentals, with an A+ for profitability but a D for valuation and an F for growth, highlighting the company's strong margins yet concerns over its growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to fall
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 129.380
Low
95.00
Averages
119.53
High
139.00
Current: 129.380
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Merck Stock Pullback but Outlook Remains Positive
- Stock Pullback: Merck (MRK) closed down 0.87% at $128.26 on Tuesday, breaking a six-session winning streak, despite a 13.62% gain during that period, outperforming the S&P 500's 0.80% decline.
- Key Drug Approval: On June 25, Merck's Keytruda in combination with Padcev was approved by the European Commission for first-line treatment of certain unresectable or metastatic urothelial carcinoma, leading to a nearly 4% stock increase that day and expanding its oncology franchise.
- Analyst Optimism: Seeking Alpha's ALLKA Research rated Merck a Buy, citing a strong oncology engine with continued momentum for Keytruda and a broad late-stage pipeline supporting long-term growth, while Gen Alpha viewed the recent stock weakness as a buying opportunity, suggesting concerns over Keytruda's patent cliff are priced in.
- Divergent Ratings: While most analysts maintain a Buy consensus on Merck, the Seeking Alpha Quant Rating system assigns a Hold rating, indicating mixed fundamentals, with an A+ for profitability but a D for valuation and an F for growth, highlighting the company's strong margins yet concerns over its growth prospects.
See More
US Terminates Emergency Authorizations for COVID-19 Treatments
- Emergency Authorization Termination: HHS Secretary Robert F. Kennedy Jr. has announced the termination of Emergency Use Authorizations for COVID-19 treatments, with drug and biologic authorizations ending in 12 months and medical devices in 180 days, potentially leading to supply constraints for these products.
- Vaccines Unaffected: Today's action does not impact the three COVID vaccines available in the US from Moderna, Pfizer/BioNTech, and Novavax, as they have received traditional approvals, ensuring the stability of vaccine supply and vaccination programs.
- Drug Impact: The directive affects drugs like Pfizer's Paxlovid and Merck's Lagrevio, which may lead to decreased availability of these treatments, thereby impacting patient options for COVID-19 care.
- Market Reaction Anticipation: The termination of emergency authorizations may elicit negative market reactions regarding future sales and R&D investments in related drugs, particularly affecting innovation and competitiveness in the COVID-19 treatment landscape.
See More
Semiconductor Stocks Surge; Watts Water Upgraded
- Semiconductor ETF Performance: The VanEck Semiconductor ETF (SMH) is on track for a 70% surge in Q2, driving chip stocks higher, with Astera Labs up 7%, KLA Corp up 8%, and Applied Materials up 5%, indicating strong market confidence in the semiconductor sector.
- Watts Water Upgrade: Watts Water Technologies jumped over 7% after Barclays upgraded its rating to overweight, as the company is seen as best positioned to benefit from the data center capital expenditures cycle with its expanding portfolio in waste and water technology.
- Abivax Stock Surge: U.S.-traded shares of French biotech company Abivax soared 40% after releasing new data on its ulcerative colitis treatment, showing malignancy rates in line with expectations and over 37% of initially non-responsive patients achieving clinical remission after about 10 months, highlighting treatment efficacy.
- Air Products Project Cancellation: Air Products and Chemicals rose over 8% after announcing it would not proceed with its Louisiana Clean Energy Complex, which is expected to incur up to $2.9 billion in pretax charges, reflecting the company's stringent financial return criteria.
See More
AeroVironment Shares Surge 30% After Earnings Beat Expectations
- Earnings Surprise: AeroVironment reported earnings of $1.84 per share and revenue of $642 million, surpassing analyst expectations of $1.46 and $559 million, leading to a 30% stock surge that underscores the company's robust performance in the drone sector.
- Acquisition Impact: Digital Realty Trust's agreement to purchase three fully leased data centers for $7.8 billion resulted in a 4.5% stock decline, raising concerns about its financial stability and prompting investors to monitor future earnings performance closely.
- Regulatory Investigation Pressure: Shares of Merck and AbbVie fell by 0.6% and 0.5%, respectively, following reports of a U.S. House committee probing their involvement in clinical trials that may have aided China's military capabilities, potentially harming their reputations and future business prospects.
- Market Volatility: Strategy stock, after a significant 22.6% gain, retraced over 3%, reflecting market sentiment instability, which necessitates cautious evaluation of its future trajectory by investors.
See More
Analysis of Three Major High Dividend ETFs
- Strong Performance of SCHD: As of June 26, 2026, the Schwab U.S. Dividend Equity ETF (SCHD) has risen over 15%, significantly outperforming the S&P 500, Nasdaq Composite, and Dow Jones, indicating its robust market performance and investment appeal.
- Diversification Advantage of VYM: The Vanguard High Dividend Yield ETF (VYM) offers a respectable 2.3% yield with 605 holdings, providing good diversification opportunities, and has doubled its dividend payout over the past decade, enhancing investor confidence.
- Growth Potential of VIG: The Vanguard Dividend Appreciation ETF (VIG) has the lowest dividend yield among the three but boasts a total return of 251% over the past decade, far exceeding SCHD and VYM, showcasing its unique advantage in growth stocks with a 28.4% allocation to tech.
- Cautious Investment Advice: Despite SCHD's strong performance, it was not included in the Motley Fool's current best stock picks, suggesting that investors should be cautious and consider potential higher return opportunities when selecting high dividend ETFs.
See More
Stable Passive Income Source: High Dividend ETFs
- Strong ETF Performance: The Schwab U.S. Dividend Equity ETF (SCHD) has shown remarkable performance in early 2026, rising over 15% and significantly outperforming the S&P 500, Nasdaq, and Dow Jones, highlighting its leadership in high-quality dividend stocks.
- Stable Dividend Yield: With a dividend yield of 3.3%, SCHD offers the highest yield among the three ETFs, and its stringent selection criteria ensure companies have a track record of 10 consecutive years of dividend increases, providing reliable passive income for long-term investors.
- Diversified Investment Options: The Vanguard High Dividend Yield ETF (VYM) offers a respectable 2.3% yield with a diversified portfolio of 605 stocks, and its dividend payouts have more than doubled over the past decade, appealing to investors seeking stable income.
- Growth Potential with Dividends: The Vanguard Dividend Appreciation ETF (VIG) has the lowest yield but boasts a total return of 251% over the past decade, far exceeding SCHD and VYM, showcasing its strength in growth stocks and appealing to investors looking for capital appreciation.
See More
Merck Stock Pullback but Outlook Remains Positive
- Stock Pullback: Merck (MRK) closed down 0.87% at $128.26 on Tuesday, breaking a six-session winning streak, despite a 13.62% gain during that period, outperforming the S&P 500's 0.80% decline.
- Key Drug Approval: On June 25, Merck's Keytruda in combination with Padcev was approved by the European Commission for first-line treatment of certain unresectable or metastatic urothelial carcinoma, leading to a nearly 4% stock increase that day and expanding its oncology franchise.
- Analyst Optimism: Seeking Alpha's ALLKA Research rated Merck a Buy, citing a strong oncology engine with continued momentum for Keytruda and a broad late-stage pipeline supporting long-term growth, while Gen Alpha viewed the recent stock weakness as a buying opportunity, suggesting concerns over Keytruda's patent cliff are priced in.
- Divergent Ratings: While most analysts maintain a Buy consensus on Merck, the Seeking Alpha Quant Rating system assigns a Hold rating, indicating mixed fundamentals, with an A+ for profitability but a D for valuation and an F for growth, highlighting the company's strong margins yet concerns over its growth prospects.
See More
US Terminates Emergency Authorizations for COVID-19 Treatments
- Emergency Authorization Termination: HHS Secretary Robert F. Kennedy Jr. has announced the termination of Emergency Use Authorizations for COVID-19 treatments, with drug and biologic authorizations ending in 12 months and medical devices in 180 days, potentially leading to supply constraints for these products.
- Vaccines Unaffected: Today's action does not impact the three COVID vaccines available in the US from Moderna, Pfizer/BioNTech, and Novavax, as they have received traditional approvals, ensuring the stability of vaccine supply and vaccination programs.
- Drug Impact: The directive affects drugs like Pfizer's Paxlovid and Merck's Lagrevio, which may lead to decreased availability of these treatments, thereby impacting patient options for COVID-19 care.
- Market Reaction Anticipation: The termination of emergency authorizations may elicit negative market reactions regarding future sales and R&D investments in related drugs, particularly affecting innovation and competitiveness in the COVID-19 treatment landscape.
See More
Semiconductor Stocks Surge; Watts Water Upgraded
- Semiconductor ETF Performance: The VanEck Semiconductor ETF (SMH) is on track for a 70% surge in Q2, driving chip stocks higher, with Astera Labs up 7%, KLA Corp up 8%, and Applied Materials up 5%, indicating strong market confidence in the semiconductor sector.
- Watts Water Upgrade: Watts Water Technologies jumped over 7% after Barclays upgraded its rating to overweight, as the company is seen as best positioned to benefit from the data center capital expenditures cycle with its expanding portfolio in waste and water technology.
- Abivax Stock Surge: U.S.-traded shares of French biotech company Abivax soared 40% after releasing new data on its ulcerative colitis treatment, showing malignancy rates in line with expectations and over 37% of initially non-responsive patients achieving clinical remission after about 10 months, highlighting treatment efficacy.
- Air Products Project Cancellation: Air Products and Chemicals rose over 8% after announcing it would not proceed with its Louisiana Clean Energy Complex, which is expected to incur up to $2.9 billion in pretax charges, reflecting the company's stringent financial return criteria.
See More
AeroVironment Shares Surge 30% After Earnings Beat Expectations
- Earnings Surprise: AeroVironment reported earnings of $1.84 per share and revenue of $642 million, surpassing analyst expectations of $1.46 and $559 million, leading to a 30% stock surge that underscores the company's robust performance in the drone sector.
- Acquisition Impact: Digital Realty Trust's agreement to purchase three fully leased data centers for $7.8 billion resulted in a 4.5% stock decline, raising concerns about its financial stability and prompting investors to monitor future earnings performance closely.
- Regulatory Investigation Pressure: Shares of Merck and AbbVie fell by 0.6% and 0.5%, respectively, following reports of a U.S. House committee probing their involvement in clinical trials that may have aided China's military capabilities, potentially harming their reputations and future business prospects.
- Market Volatility: Strategy stock, after a significant 22.6% gain, retraced over 3%, reflecting market sentiment instability, which necessitates cautious evaluation of its future trajectory by investors.
See More
Analysis of Three Major High Dividend ETFs
- Strong Performance of SCHD: As of June 26, 2026, the Schwab U.S. Dividend Equity ETF (SCHD) has risen over 15%, significantly outperforming the S&P 500, Nasdaq Composite, and Dow Jones, indicating its robust market performance and investment appeal.
- Diversification Advantage of VYM: The Vanguard High Dividend Yield ETF (VYM) offers a respectable 2.3% yield with 605 holdings, providing good diversification opportunities, and has doubled its dividend payout over the past decade, enhancing investor confidence.
- Growth Potential of VIG: The Vanguard Dividend Appreciation ETF (VIG) has the lowest dividend yield among the three but boasts a total return of 251% over the past decade, far exceeding SCHD and VYM, showcasing its unique advantage in growth stocks with a 28.4% allocation to tech.
- Cautious Investment Advice: Despite SCHD's strong performance, it was not included in the Motley Fool's current best stock picks, suggesting that investors should be cautious and consider potential higher return opportunities when selecting high dividend ETFs.
See More
Stable Passive Income Source: High Dividend ETFs
- Strong ETF Performance: The Schwab U.S. Dividend Equity ETF (SCHD) has shown remarkable performance in early 2026, rising over 15% and significantly outperforming the S&P 500, Nasdaq, and Dow Jones, highlighting its leadership in high-quality dividend stocks.
- Stable Dividend Yield: With a dividend yield of 3.3%, SCHD offers the highest yield among the three ETFs, and its stringent selection criteria ensure companies have a track record of 10 consecutive years of dividend increases, providing reliable passive income for long-term investors.
- Diversified Investment Options: The Vanguard High Dividend Yield ETF (VYM) offers a respectable 2.3% yield with a diversified portfolio of 605 stocks, and its dividend payouts have more than doubled over the past decade, appealing to investors seeking stable income.
- Growth Potential with Dividends: The Vanguard Dividend Appreciation ETF (VIG) has the lowest yield but boasts a total return of 251% over the past decade, far exceeding SCHD and VYM, showcasing its strength in growth stocks and appealing to investors looking for capital appreciation.
See More
